Hos dialysepatienter med terminal nyresygdom, gav enkeltdoser af BYETTA 5 µg flere og værre gastrointestinale bivirkninger.
In patients with end-stage renal disease receiving dialysis, single doses of BYETTA 5 µg increased frequency and severity of undesirable gastrointestinal effects.